• OPEN AN ACCOUNT
Indian Indices
Sensex
81,592.45 -318.56
( -0.39%)
Global Indices
Nasdaq
52,431.30 -76.19
(-0.15%)
Dow Jones
7,621.14 -19.24
(-0.25%)
Hang Seng
61,109.24 289.88
(0.48%)
Nikkei 225
10,906.25 43.16
(0.40%)
Forex
USD-INR
93.72 0.15
(0.16%)
EUR-INR
104.27 -0.51
(-0.49%)
GBP-INR
124.72 -0.66
(-0.52%)
JPY-INR
0.59 0.00
(-0.43%)

EQUITY - MARKET SCREENER

Jindal Stainless Ltd
Industry :  Steel - Large
BSE Code
ISIN Demat
Book Value()
532508
INE220G01021
243.2696185
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
JSL
21.21
58653.33
EPS(TTM)
Face Value()
Div & Yield %
33.55
2
0.56
 

Dr Reddys signs agreement for distribution of Takeda's dengue vaccine in India
Sep 18,2026
Dr Reddys Laboratories and Takeda Pharmaceutical Company, through its Indian subsidiary Takeda Biopharmaceuticals India, have today entered into a distribution agreement under which Dr. Reddy's will promote and distribute Takeda's dengue vaccine, QDENGA®, across India's private market for pediatric and adult vaccination in India. Subject to completion of applicable processes with local authorities, the vaccine is anticipated to become available in the first half of 2027.

The collaboration follows the approval of QDENGA's marketing authorization by India's Central Drugs Standard Control Organization (CDSCO) in July 2026 for individuals aged 4-60 years. As India's first approved dengue vaccine, the approval marks an important milestone in the country's efforts to strengthen dengue prevention and management.